Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998–2004.

References

• Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890–5
   PubMed Web of Science ®Google Scholar
• Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618–24
   PubMed Web of Science ®Google Scholar
• Catane R, Lichter A, Lee YJ, Brereton HD, Schwade JG, Glatstein E. Small cell lung cancer: Analyses of treatment factors contributing to long term survival. Cancer 1981; 48: 1936
   PubMedGoogle Scholar
• Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited stage small cell lung cancer. J Clin Oncol 2004; 22: 4837–45
   PubMed Web of Science ®Google Scholar
• Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee BC, et al. Importance of timing of thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11: 336
   PubMed Web of Science ®Google Scholar
• Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265–71
   PubMed Web of Science ®Google Scholar
• Cancer Care Ontario. The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited stage small cell lung cancer: Practice guidelines report 7-3-3, 1/03 update. http://www.cancercare.on.ca/pdf/full7_13_3.pdf.
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomised study. J Clin Oncol 1997; 15: 893–900
   PubMed Web of Science ®Google Scholar
• Coy P, Hodson I, Payne DG, Evans WK, Feld R, MacDonald AS, et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 14: 219–26
   PubMedGoogle Scholar
• De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systemic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage small-cell lung cancer. Ann Oncol 2006; 17: 543–52
   PubMed Web of Science ®Google Scholar
• Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Eng J Med 1999; 341: 476–84
   PubMed Web of Science ®Google Scholar
• Meert AP, Paesman M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: A systemic review of the literature with meta-analysis. BMC Cancer 2001; 1: 5
   PubMed Web of Science ®Google Scholar
• Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomised comparison of etoposide-cisplatin versus etoposid-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group Study. Ann Oncol 1994; 5: 601–7
   PubMed Web of Science ®Google Scholar
• Lassen U, Kritjansen K, Osterlind K, Bergman B, Sigsgaard TC, Hirsch FR, et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomised trial with 5 years follow up. Ann Oncol 1996; 7: 365–71
   PubMed Web of Science ®Google Scholar
• Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Hellenic Cooperative Oncology group for Lung Cancer Trials. Semin Oncol 1994; 21: 23–30
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Lorigan P, West C, Thatcher N. Thoracic radiation therapy for limited-stage small cell lung cancer: Unanswered question. Clin Lung Cancer 2005; 7: 23–9
   PubMedGoogle Scholar
• Faivre-Finn C, Lee LW, Lorigan P, West C, Thatcher N. Thoracic radiotherapy for limited-stage small cell lung cancer: Controversies and future developments. Clin Oncol 2005; 17: 591–8
   Google Scholar
• Stuschke M, Pöttgen C. Localized small cell lung cancer: Which type of thoracic radiotherapy and which time schedule. Lung cancer 2004; 45: 133–7
   Google Scholar
• Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20: 3054–60
   PubMed Web of Science ®Google Scholar
• Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17: 2681–91
   PubMed Web of Science ®Google Scholar
• Papac RJ, Son Y, Bien R, Tiedemann D, Keohane M, Yesner R. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cycle chemotherapy. J Radiat Oncol 1987; 13: 993–8
   PubMed Web of Science ®Google Scholar
• Bogart JA, Herndon II JE, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of cancer and leukaemia group B study 39808. Int J Rad Oncol Biol Phys 2004; 59: 460–8
   PubMed Web of Science ®Google Scholar
• Janne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95: 1528–38
   PubMed Web of Science ®Google Scholar
• Weinmann M, Zimmermann F, Bamberg M, Jeremic B. Curative approaches to lung cancer in the elderly. Semin Surg Oncol 2003; 21: 182–9
   PubMedGoogle Scholar
• Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848–52
   PubMed Web of Science ®Google Scholar
• Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, et al. Ifosfamide, carboplatin and etoposide with mid-cycle vincristine versus standard chemotherapy in patients with small cell lung cancer and good performance status: Clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005; 23: 8371–9
   PubMedGoogle Scholar